November 2021 - Page 3 of 3 - PsychedelicNewsWire (PNW)

TuesdayNov 09, 2021 11:45 am

Overview of Major Sectors Making Up Psychedelics Industry

The psychedelics industry has grown tremendously these last few years, offering new opportunities for investors interested in this space. The potential for the substance to revolutionize the field of medicine has prompted a significant increase in the capital being injected into the multibillion dollar industry, which has facilitated further development. Below is an overview of the major sectors making up this industry. R&D and Clinical Trials This refers to clinical and/or research and development trials that involve psychedelic substances. Currently, there are more than 12 companies conducting phase 2 clinical trials on psychedelic drug candidates and a nonprofit called MAPS…

MondayNov 08, 2021 2:00 pm

Italian Activists Submit More than 600,000 Signatures for Psychedelic Referendum

Last week, activists in Italy submitted more than 600,000 signatures for a referendum to legalize cannabis cultivation as well as the growing of other psychoactive fungi and plants such as magic mushrooms. The reform campaign hopes that with these signatures, their measure, which was filed in September, will be brought before voters next year. The activists were able to collect a high number of signatures because of a change in policy that permitted them to gather signatures in person as well as online. It should be noted that before the measure is brought before the voters, some steps need to…

FridayNov 05, 2021 1:15 pm

UK Prime Minister Boris Johnson to Consider Rescheduling Psilocybin

Psilocybin is a naturally occurring active hallucinogenic compound found in magic mushrooms, which is consumed for its hallucinogenic effects. Recently, Crispin Blunt, a member of the Conservative Party in the United Kingdom, urged UK Prime Minister Boris Johnson to review the laws on psychedelics, particularly psilocybin, and allow more studies on the substance’s therapeutic qualities to be conducted. Blunt explained that psilocybin possessed significant potential for the treatment of various mental health disorders, including addiction, trauma and depression. Research has also found that psilocybin may be used to manage treatment-resistant depression as well as anxiety with researchers also looking into…

FridayNov 05, 2021 9:00 am

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7).…

ThursdayNov 04, 2021 12:49 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

ThursdayNov 04, 2021 12:15 pm

Could This Music Studio’s Fundraiser Signal Investor Confidence in Psychedelics Industry?

While the therapeutic psychedelic industry segment grows, plenty of institutional investors seem to be seeing plenty of opportunities in companies that address the needs of the core players in the psychedelics space. Such support directed at ancillary businesses is a tacit acknowledgment that an industry is headed towards maturity and permanency. That trajectory towards maturity gives investors confidence that they may also see decent returns from the ancillary companies, as one music studio has discovered. Wavepaths was created solely to come up with music customized for psychedelic therapy. The studio bagged $4.5 million in a funding round that closed last…

WednesdayNov 03, 2021 3:00 pm

Psychedelics Group Dispatches First Batch of Grants in Support of Entheogenic User Education

Plant Medicine Coalition (“PMC”), a nonprofit based in Washington D.C. has issued about $50,000 in grants to about 12 groups in D.C. The funds are intended to facilitate those community groups in their efforts to spread awareness about plant medicine and how people can benefit from it. PMC traces its origins to the leader of the group, which spearheaded the campaign that saw entheogenic plants as well as fungi decriminalized in the capital during the elections in November last year. The money that PMC issued to the community groups was provided by a wellness company called Dr. Bronner’s. This company…

TuesdayNov 02, 2021 1:00 pm

New Study Questions Purported Value of Classical Music During Psychedelic Therapy

A study has found that playing overtone-based music in psychedelic therapy is more beneficial than playing classical music. For some time now, psychedelic therapy has made use of Western classical music, with some cited works even recommending the genre’s use. However, new research has found that individual differences in music preference may influence therapeutic outcomes in sessions that involve the use of music. Justin C. Strickland and his colleagues Matthew W. Johnson and Albert Garcia-Romeu carried out an analysis of data collected from an open-label study on the use of psilocybin in stopping smoking, in order to assess the impact…

MondayNov 01, 2021 3:00 pm

City Council of Easthampton Approves Psychedelics Reform Measure

Last week, the city council of Easthampton, Massachusetts, passed a psychedelics initiative that calls for some drugs and entheogenic substances to be decriminalized. The initiative, which was approved in a 7 to 0 vote, had been filed by Owen Zaret, a member of the City Council. The effort was spearheaded by Bay Staters for Natural Medicine (baystatersnm.org), a group of grassroots volunteers that has passed near-identical resolutions in three other Massachusetts cities. After the vote, Zaret stated in an interview that he felt indebted to the council for being forward thinking, noting that this progress would allow individuals to access…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: November 2021